{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T21:29:45Z","timestamp":1784064585486,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"47","license":[{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2021,11,25]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>RNF6 is a RING finger protein with oncogenic potential. In this study, we established colon-specific RNF6 transgenic (tg) mice, and demonstrated that RNF6 overexpression accelerated colorectal carcinogenesis compared to wild-type littermates in a chemically induced colorectal cancer (CRC) model. To understand whether transcriptional activity of RNF6 underlies its oncogenic effect, we performed integrated chromatin immunoprecipitation (ChIP)-sequencing and RNA-sequencing analysis to identify splicing factor 3b subunit 2 (SF3B2) as a potential downstream target of RNF6. RNF6 binds to the SF3B2 promoter and the overexpression of RNF6 activates SF3B2 expression in CRC cells, primary CRC organoids, and RNF6 tg mice. SF3B2 knockout abrogated the tumor promoting effect of RNF6 overexpression, whereas the reexpression of SF3B2 recused cell growth and migration\/invasion in RNF6 knockout cells, indicating that SF3B2 is a functional downstream target of RNF6 in CRC. Targeting of RNF6-SF3B2 axis with SF3B2 inhibitor with pladienolide B suppressed the growth of CRC cells with RNF6 overexpression in vitro and in vivo. Moreover, the combination of 5-fluorouracil (5-FU) plus pladienolide B exerted synergistic effects in CRC with high RNF6 expression, leading to tumor regression in xenograft models. These findings indicate that tumor promoting effect of RNF6 is achieved mainly via transcriptional upregulation of SF3B2, and that RNF6-SF3B2 axis is a promising target for CRC therapy.<\/jats:p>","DOI":"10.1038\/s41388-021-01872-9","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T16:40:17Z","timestamp":1633452017000},"page":"6513-6526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["RING-finger protein 6 promotes colorectal tumorigenesis by transcriptionally activating SF3B2"],"prefix":"10.1038","volume":"40","author":[{"given":"Hui","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1362-3541","authenticated-orcid":false,"given":"Chi Chun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5172-9932","authenticated-orcid":false,"given":"Lifu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3452-4323","authenticated-orcid":false,"given":"Lei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5008-2153","authenticated-orcid":false,"given":"Jun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,5]]},"reference":[{"key":"1872_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD. Cancer statistics. CA Cancer J Clin. 2020;70:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"1872_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3322\/caac.21601","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD. Colorectal cancer statistics. CA Cancer J Clin. 2020;70:145\u201364.","journal-title":"CA Cancer J Clin"},{"key":"1872_CR3","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nrg3539","volume":"14","author":"IR Watson","year":"2013","unstructured":"Watson IR, Takahashi K, Futreal PA, Chin L. Emerging patterns of somatic mutations in cancer. Nat Rev Genet. 2013;14:703\u201318.","journal-title":"Nat Rev Genet"},{"key":"1872_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-pathol-011110-130235","volume":"6","author":"ER Fearon","year":"2011","unstructured":"Fearon ER. Molecular genetics of colorectal cancer. Ann Rev Pathol. 2011;6:479\u2013507.","journal-title":"Ann Rev Pathol"},{"key":"1872_CR5","doi-asserted-by":"publisher","first-page":"18654","DOI":"10.1073\/pnas.0704652104","volume":"104","author":"L Shen","year":"2007","unstructured":"Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA. 2007;104:18654\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1872_CR6","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/gutjnl-2014-308257","volume":"65","author":"L Xu","year":"2016","unstructured":"Xu L, Li X, Cai M, Chen J, Li X, Wu WK, et al. Increased expression of Solute carrier family 12 member 5 via gene amplification contributes to tumour progression and metastasis and associates with poor survival in colorectal cancer. Gut 2016;65:635\u201346.","journal-title":"Gut"},{"key":"1872_CR7","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1158\/0008-5472.CAN-17-2683","volume":"78","author":"L Liu","year":"2018","unstructured":"Liu L, Zhang Y, Wong CC, Zhang J, Dong Y, Li X, et al. RNF6 promotes colorectal cancer by activating the Wnt\/beta-catenin pathway via ubiquitination of TLE3. Cancer Res. 2018;78:1958\u201371.","journal-title":"Cancer Res"},{"key":"1872_CR8","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1158\/1078-0432.CCR-17-2133","volume":"24","author":"Q Liang","year":"2018","unstructured":"Liang Q, Ma D, Zhu X, Wang Z, Sun TT, Shen C, et al. RING-finger protein 6 amplification activates JAK\/STAT3 pathway by modifying SHP-1 ubiquitylation and associates with poor outcome in colorectal cancer. Clin Cancer Res. 2018;24:1473\u201385.","journal-title":"Clin Cancer Res"},{"key":"1872_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.yexcr.2018.11.019","volume":"374","author":"J Cai","year":"2019","unstructured":"Cai J, Xiong Q, Jiang X, Zhou S, Liu T. RNF6 facilitates metastasis and radioresistance in hepatocellular carcinoma through ubiquitination of FoxA1. Exp Cell Res. 2019;374:152\u201361.","journal-title":"Exp Cell Res"},{"key":"1872_CR10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ccr.2009.02.021","volume":"15","author":"K Xu","year":"2009","unstructured":"Xu K, Shimelis H, Linn DE, Jiang R, Yang X, Sun F, et al. Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell. 2009;15:270\u201382.","journal-title":"Cancer Cell"},{"key":"1872_CR11","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s41401-019-0309-6","volume":"41","author":"Y Ren","year":"2020","unstructured":"Ren Y, Xu X, Mao CY, Han KK, Xu YJ, Cao BY, et al. RNF6 promotes myeloma cell proliferation and survival by inducing glucocorticoid receptor polyubiquitination. Acta Pharm Sin. 2020;41:394\u2013403.","journal-title":"Acta Pharm Sin"},{"key":"1872_CR12","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1128\/MCB.22.10.3488-3496.2002","volume":"22","author":"P Lopez","year":"2002","unstructured":"Lopez P, Vidal F, Martin L, Lopez-Fernandez LA, Rual JF, Rosen BS, et al. Gene control in germinal differentiation: RNF6, a transcription regulatory protein in the mouse sertoli cell. Mol Cell Biol. 2002;22:3488\u201396.","journal-title":"Mol Cell Biol"},{"key":"1872_CR13","doi-asserted-by":"publisher","first-page":"6517","DOI":"10.7150\/thno.34989","volume":"9","author":"Y Dong","year":"2019","unstructured":"Dong Y, Zhang Y, Kang W, Wang G, Chen H, Higashimori A, et al. VSTM2A suppresses colorectal cancer and antagonizes Wnt signaling receptor LRP6. Theranostics 2019;9:6517\u201331.","journal-title":"Theranostics"},{"key":"1872_CR14","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/nprot.2007.279","volume":"2","author":"C Neufert","year":"2007","unstructured":"Neufert C, Becker C, Neurath MF. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc. 2007;2:1998\u20132004.","journal-title":"Nat Protoc"},{"key":"1872_CR15","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1158\/0008-5472.CAN-18-3965","volume":"79","author":"N Kawamura","year":"2019","unstructured":"Kawamura N, Nimura K, Saga K, Ishibashi A, Kitamura K, Nagano H, et al. SF3B2-mediated RNA splicing drives human prostate cancer progression. Cancer Res. 2019;79:5204\u201317.","journal-title":"Cancer Res"},{"key":"1872_CR16","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1158\/0008-5472.CAN-17-2683","volume":"78","author":"L Liu","year":"2018","unstructured":"Liu L, Zhang Y, Wong CC, Zhang J, Dong Y, Li X, et al. RNF6 promotes colorectal cancer by activating the Wnt\/\u03b2-catenin pathway via ubiquitination of TLE3. Cancer Res. 2018;78:1958\u201371.","journal-title":"Cancer Res"},{"key":"1872_CR17","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440\u20136.","journal-title":"Cancer Res"},{"key":"1872_CR18","doi-asserted-by":"publisher","first-page":"9617","DOI":"10.1074\/jbc.M115.701979","volume":"291","author":"X Xu","year":"2016","unstructured":"Xu X, Han K, Tang X, Zeng Y, Lin X, Zhao Y, et al. The ring finger protein RNF6 induces leukemia cell proliferation as a direct target of pre-B-cell leukemia homeobox 1. J Biol Chem. 2016;291:9617\u201328.","journal-title":"J Biol Chem"},{"key":"1872_CR19","first-page":"4191","volume":"62","author":"HS Lo","year":"2002","unstructured":"Lo HS, Hu N, Gere S, Lu N, Su H, Goldstein AM, et al. Identification of somatic mutations of the RNF6 gene in human esophageal squamous cell carcinoma. Cancer Res. 2002;62:4191\u20133.","journal-title":"Cancer Res"},{"key":"1872_CR20","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1158\/2159-8290.CD-15-0493","volume":"5","author":"K Rai","year":"2015","unstructured":"Rai K, Akdemir KC, Kwong LN, Fiziev P, Wu CJ, Keung EZ, et al. Dual roles of RNF2 in melanoma progression. Cancer Disco. 2015;5:1314\u201327.","journal-title":"Cancer Disco"},{"key":"1872_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.molcel.2016.08.036","volume":"64","author":"C Cretu","year":"2016","unstructured":"Cretu C, Schmitzova J, Ponce-Salvatierra A, Dybkov O, De Laurentiis EI, Sharma K, et al. Molecular architecture of SF3b and structural consequences of its cancer-related mutations. Mol Cell. 2016;64:307\u201319.","journal-title":"Mol Cell"},{"key":"1872_CR22","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nchembio.2007.16","volume":"3","author":"Y Kotake","year":"2007","unstructured":"Kotake Y, Sagane K, Owa T, Mimori-Kiyosue Y, Shimizu H, Uesugi M, et al. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol. 2007;3:570\u20135.","journal-title":"Nat Chem Biol"},{"key":"1872_CR23","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/cas.12317","volume":"105","author":"M Sato","year":"2014","unstructured":"Sato M, Muguruma N, Nakagawa T, Okamoto K, Kimura T, Kitamura S, et al. High antitumor activity of pladienolide B and its derivative in gastric cancer. Cancer Sci. 2014;105:110\u20136.","journal-title":"Cancer Sci"},{"key":"1872_CR24","doi-asserted-by":"publisher","first-page":"6064","DOI":"10.1158\/1078-0432.CCR-13-2461","volume":"19","author":"SM Dehm","year":"2013","unstructured":"Dehm SM. Test-firing ammunition for spliceosome inhibition in cancer. Clin Cancer Res. 2013;19:6064\u20136.","journal-title":"Clin Cancer Res"},{"key":"1872_CR25","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s10637-013-0046-5","volume":"32","author":"DS Hong","year":"2014","unstructured":"Hong DS, Kurzrock R, Naing A, Wheler JJ, Falchook GS, Schiffman JS, et al. A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Invest N. Drugs. 2014;32:436\u201344.","journal-title":"Invest N. Drugs"},{"key":"1872_CR26","doi-asserted-by":"publisher","first-page":"6296","DOI":"10.1158\/1078-0432.CCR-13-0485","volume":"19","author":"FA Eskens","year":"2013","unstructured":"Eskens FA, Ramos FJ, Burger H, O\u2019Brien JP, Piera A, de Jonge MJ, et al. Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors. Clin Cancer Res. 2013;19:6296\u2013304.","journal-title":"Clin Cancer Res"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01872-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01872-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01872-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T10:03:23Z","timestamp":1637834603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01872-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,5]]},"references-count":26,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2021,11,25]]}},"alternative-id":["1872"],"URL":"https:\/\/doi.org\/10.1038\/s41388-021-01872-9","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,5]]},"assertion":[{"value":"9 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}